Threshold Pharmaceuticals (NASDAQ:THLD), A increase of 276,888 shares or 10.6% was observed in the short interest of Threshold Pharmaceuticals, Inc. The interest on June 15,2016 came in at 2,902,050 shares and as per the average daily trading of 584,562 shares, the days to cover are 5. The increased interest is 4.5% of the floated shares. The data of May 31,2016 put the interest at 2,625,162 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Threshold Pharmaceuticals (NASDAQ:THLD): The stock opened at $0.35 on Friday but the bulls could not build on the opening and the stock topped out at $0.39 for the day. The stock traded down to $0.35 during the day, due to lack of any buying support eventually closed down at $0.38 with a loss of -6.93% for the day. The stock had closed at $0.41 on the previous day. The total traded volume was 5,848,945 shares.
The company shares have dropped -90.36% from its 1 Year high price. On Sep 18, 2015, the shares registered one year high at $5.28 and the one year low was seen on Feb 24, 2016. The 50-Day Moving Average price is $0.42 and the 200 Day Moving Average price is recorded at $0.41.
Threshold Pharmaceuticals (NASDAQ:THLD) has tumbled 5% during the past week and has dropped 20.75% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 3.42%. Threshold Pharmaceuticals (NASDAQ:THLD) has underperformed the index by 18.35% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Threshold Pharmaceuticals, Inc. (Threshold) is a biotechnology company engaged in the discovery and development of therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Thresholds investigational small molecule, evofosfamide, is being evaluated in two Phase III clinical trials, one registrational Phase II clinical trial and various earlier-stage clinical trials for the treatment of various diseases, such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), advanced melanoma, multiple myeloma and advanced solid tumors. Threshold has also licensed rights to a development program based on the clinical-stage oncology compound TH-4000, a hypoxia-targeted epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor. Thresholds [18F]-HX4 is an investigational Positron Emission Tomography (PET) imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.